Robert Glanzman's most recent trade in Clene Inc was a trade of 4,717 Common Stock done at an average price of $2.0 . Disclosure was reported to the exchange on May 16, 2022.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Clene Inc | Robert Glanzman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 2.03 per share. | 16 May 2022 | 4,717 | 10,564 | - | 2.0 | 9,576 | Common Stock |
Clene Inc | Robert Glanzman | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 140,000 | 140,000 | - | - | Stock Options (Right to buy) | |
Clene Inc | Robert Glanzman | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Nov 2021 | 100,000 | 100,000 | - | - | Stock Options (Right to buy) | |
Clene Inc | Robert Glanzman | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 15,281 | 15,281 | - | 0 | Common Stock | |
Clene Inc | Robert Glanzman | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2021 | 95,000 | 95,000 | - | - | Stock Options (Right to buy) |